Researchers isolate human monoclonal antibodies that may neutralize several norovirus variants
Researchers at Vanderbilt University Medical Center (VUMC) and the Baylor College of Medicine in Houston, Texas, have taken a big step toward developing targeted treatments and vaccines against a family of viruses that attacks the gastrointestinal tract.
Each year in the United States circulating strains of the human norovirus are responsible for approximately 20 million cases of acute gastroenteritis. Hallmark symptoms include severe abdominal cramping, diarrhea and vomiting.
Several vaccine candidates are in clinical trials, but it is unclear how effective they will be, given the periodic emergence of novel norovirus variants. Developing broadly effective vaccines will require an understanding of the genetic diversity of the virus and the mechanisms by which the immune system can neutralize it.
Study identifies monoclonal antibodies that may neutralize many norovirus variants
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Study identifies monoclonal antibodies that may neutralize many norovirus variants
johnsoncitypress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from johnsoncitypress.com Daily Mail and Mail on Sunday newspapers.
Robert Siegel
kasu.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kasu.org Daily Mail and Mail on Sunday newspapers.
Researchers identify a common mechanism underlying diverse brain disorders
Researchers at Vanderbilt University Medical Center (VUMC) have identified a common mechanism underlying a spectrum of epilepsy syndromes and neurodevelopmental disorders, including autism, that are caused by variations in a gene encoding a vital transporter protein in the brain.
Their findings, reported last month in the journal
Brain, suggest that boosting transporter function via genetic or pharmacological means could be beneficial in treating brain disorders linked to these genetic variations.
This points to a clear direction of treating a wide spectrum of neurodevelopmental disorders, from various epilepsy syndromes (and) autism to neurodevelopmental delay and intellectual disabilities, caused by the pathological variants in this gene.